ATE249829T1 - Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress - Google Patents

Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress

Info

Publication number
ATE249829T1
ATE249829T1 AT97100145T AT97100145T ATE249829T1 AT E249829 T1 ATE249829 T1 AT E249829T1 AT 97100145 T AT97100145 T AT 97100145T AT 97100145 T AT97100145 T AT 97100145T AT E249829 T1 ATE249829 T1 AT E249829T1
Authority
AT
Austria
Prior art keywords
nitroxides
oxidative stress
oxazolidines
protect
ionizing radiation
Prior art date
Application number
AT97100145T
Other languages
English (en)
Inventor
William G Degraff
James B Mitchell
Stephen Hahn
Amram Samuni
Original Assignee
Us Secretary United States Dep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Secretary United States Dep filed Critical Us Secretary United States Dep
Application granted granted Critical
Publication of ATE249829T1 publication Critical patent/ATE249829T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Dental Preparations (AREA)
  • Pyrrole Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97100145T 1990-03-16 1991-03-18 Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress ATE249829T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49453290A 1990-03-16 1990-03-16

Publications (1)

Publication Number Publication Date
ATE249829T1 true ATE249829T1 (de) 2003-10-15

Family

ID=23964864

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97100145T ATE249829T1 (de) 1990-03-16 1991-03-18 Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress
AT91906494T ATE157249T1 (de) 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91906494T ATE157249T1 (de) 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion

Country Status (10)

Country Link
US (1) US5462946A (de)
EP (2) EP0520005B1 (de)
JP (1) JP2741427B2 (de)
AT (2) ATE249829T1 (de)
AU (1) AU644865B2 (de)
CA (1) CA2078287C (de)
DE (2) DE69127437T2 (de)
DK (1) DK0787492T3 (de)
ES (1) ES2207690T3 (de)
WO (1) WO1991013619A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US6605619B1 (en) 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
AU720476B2 (en) * 1996-05-07 2000-06-01 Eric F. Bernstein Use of tempol in the prevention of photoaging
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
JP2002524471A (ja) 1998-09-09 2002-08-06 ベイカー ヒューズ インコーポレイテッド ヒンダードヒドロキシルアミンを使用したビニルモノマーの重合禁止剤
CA2377621C (en) * 1999-06-23 2009-05-19 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
WO2002026231A1 (en) * 2000-09-26 2002-04-04 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
AU2003243282B2 (en) 2002-05-17 2008-05-01 Othera Holding, Inc. Amelioration of the development of cataracts and other opthalmic diseases
WO2004030623A2 (en) * 2002-10-01 2004-04-15 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
JP2006524701A (ja) * 2003-04-25 2006-11-02 ミトス・インコーポレーテッド 酸化防止剤による予防的前処置
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
WO2006084198A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing immunological diseases
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
US20090042937A1 (en) * 2005-02-02 2009-02-12 Louis Habash Nitroxides for use in treating or preventing amyloid-related diseases
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
CA2617962A1 (en) * 2005-08-11 2007-02-22 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Method for determining redox status of a tissue
CA2632183A1 (en) 2005-08-25 2007-03-01 Philip R. Houle Treatment systems for delivery of sensitizer solutions
US7538130B2 (en) * 2005-09-26 2009-05-26 Basf Corporation Hindered amine light stabilizer, methods of making, and compositions
US20070160642A1 (en) * 2006-01-12 2007-07-12 Pacetti Stephen D Implantable medical devices coated with a polymer-bound superoxide dismutase mimic
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
WO2008013660A2 (en) * 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
EP2121599A4 (de) * 2006-11-29 2011-01-19 Mitos Pharmaceuticals Inc Nitroxide zur behandlung oder vorbeugung von hypercholesterinämie
EP2120942A2 (de) * 2007-02-16 2009-11-25 Othera Holding, Inc. Medikamentenresistenzumkehrung bei neoplastischen krankheiten
WO2008112647A2 (en) * 2007-03-09 2008-09-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitroxide radical as a treatment for neurodegeneration
US7820963B2 (en) * 2007-08-06 2010-10-26 Metabolic Alayses, Inc. Method for generation and use of isotopic patterns in mass spectral data of simple organisms
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2011018472A2 (en) 2009-08-14 2011-02-17 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US20110130421A1 (en) * 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US20170000377A1 (en) * 2014-03-14 2017-01-05 The General Hospital Corporation System and method for imaging free radicals
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
CA3097468A1 (en) 2018-04-16 2019-10-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
AU2020319888A1 (en) 2019-08-01 2022-02-24 Praetego, Inc. Inhibitors of advanced glycation end products
US12208089B2 (en) 2021-05-25 2025-01-28 Louis Habash Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
WO1988005653A1 (en) * 1987-01-28 1988-08-11 Proctor Peter H Topical composition for stimulating hair growth with stable free radicals

Also Published As

Publication number Publication date
EP0520005B1 (de) 1997-08-27
DE69127437T2 (de) 1998-02-05
US5462946A (en) 1995-10-31
EP0520005A4 (en) 1993-04-21
WO1991013619A1 (en) 1991-09-19
EP0787492B1 (de) 2003-09-17
JPH05501114A (ja) 1993-03-04
EP0787492A1 (de) 1997-08-06
DE69133313T2 (de) 2004-07-01
EP0520005A1 (de) 1992-12-30
CA2078287C (en) 1996-11-26
ATE157249T1 (de) 1997-09-15
DE69133313D1 (de) 2003-10-23
DE69127437D1 (de) 1997-10-02
AU644865B2 (en) 1993-12-23
DK0787492T3 (da) 2004-02-02
AU7542391A (en) 1991-10-10
ES2207690T3 (es) 2004-06-01
CA2078287A1 (en) 1991-09-17
JP2741427B2 (ja) 1998-04-15

Similar Documents

Publication Publication Date Title
DE69133313D1 (de) Verwendung von Nitroxiden und Oxazolidinen zum Schutz ionisierender Strahlung und oxidativem Stress
NO803717L (no) Overflateaktive kvartaernaer ammoniumforbindelse for behandling av tekstil og cellulosematerialer
DE69133084D1 (de) Schutzüberzug und verwendung desselben
ID21704A (id) Turunan-turunan triazin simetrik
DE69223157D1 (de) Sauerstoff-substituierte derivate von nucleophil-stickstoffoxid-addukten und ihre verwendung als stickstoffoxid-donor-prodrugs
NO810814L (no) Apparat og fremgangsmaate for behandling av organiske materialer
FI891914A0 (fi) Laite vahingollisten aineiden termistä hajottamista varten
NO990542L (no) K-252a-derivater og anvendelse av K-252a-derivater
SE7802899L (sv) Komposition och sett for behandling av keratinmaterial med katjoniska och anjoniska polymerer
FI930455A7 (fi) Yhdisteitä ja menetelmiä geeniekspression inhiboimiseksi
DE69332460D1 (de) Gebrauchsverfahren von strahlungsempfindlichen Materialien
DE69123915D1 (de) Indol-Verbindungen und deren Verwendung
DE69132183D1 (de) Schutz von Vorrichtungen
NO944406D0 (no) Nye 7 se inhibitorer
PT87618A (pt) Process for the preparation of polymeric hinderd amine light stabilizers and organic compositions therewith
DE68917131D1 (de) Anordnung zur detektion und behandlung von optischer strahlung.
NO148548C (no) Pakning og fremgangsmaate for beskyttelse av oksyderbare forbindelser
SE7910073L (sv) Forfarande for behandling av organiska material
IT7850592A0 (it) Procedimento per la sbianca e la sbozzimatura di materiali tessili
DE69217003D1 (de) N-phenyl-benzamide zum schutz vor den schädlichen wirkungen von ultraviolettlicht
DE69132054D1 (de) Behandlung von windelausschlag
NO171798C (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer
SE7813277L (sv) Komposition och sett for behandling av hypertension
ATE3935T1 (de) Schaedlingsbekaempfungsmittel, die substituierte benzazole enthalten, und deren verwendung.
DE69128443D1 (de) Unsymmetrische Dioxazinverbindungen und Verfahren zum Färben oder Bedrucken von Fasermaterialien mittels derselben

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0787492

Country of ref document: EP

EELA Cancelled due to lapse of time